Atreca, Inc. (BCEL) Stock Analysis
DELISTED
What happened to Atreca, Inc. (BCEL) stock?
Atreca, Inc. (BCEL) no longer trades on public markets. The figures below are historical and are not a current quote.
- Status:
- Delisted — no longer trades
Market cap $3.57M is the value of all shares combined.
For informational purposes only. Not financial advice. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
Atreca, Inc. (BCEL). Atreca, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing antibody-based immunotherapeutics for solid tumors. Their lead product candidate, ATRC-101, targets a novel mechanism of action derived from their proprietary discovery platform.
Last analyzed: May 10, 2026Atreca, Inc. (BCEL) Healthcare & Pipeline Overview
More about this archive record
Can I still buy BCEL shares?
No. BCEL stopped trading on public markets, so the shares are not available through a broker. Anything you see quoted for BCEL elsewhere is historical data, not a live market.
Are the figures on this page current?
No. Every number here is the last value recorded before BCEL stopped trading. Nothing on this page updates, and none of it is a current quote.
Why does this page still exist?
Because people still search for what happened to Atreca, Inc.. An archived profile that states the delisting plainly is more useful than a dead link — provided it is labelled as history, which is what this page does.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.